Although patients with these tumors are clinically high-risk, they have elevated infiltrating anti-tumor immune cells, such as NK-cells and CD8+ T-cells and higher immune cytotoxic activity reflected by cytolytic scores, in contrast to Cluster 1 tumors (Table 1; Figure 2E–2F). This evidence concerns the gene CD8A and neoplasm.